Implantable Cardioverter Defibrillators (ICDs) Market Report 2025

This Implantable Cardioverter Defibrillators (ICDs) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The implantable cardioverter defibrillators (ICDs) market size has grown strongly in recent years. It will grow from $3.76 billion in 2024 to $3.99 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth observed during the historical period can be linked to several factors, including the rising incidence of sudden cardiac arrest, the integration of implantable cardioverter defibrillators in the secondary prevention of such events, enhanced public awareness, the aging population, favorable policies from governments and healthcare organizations, and improved access to healthcare.

The implantable cardioverter defibrillators (ICDs) market size is expected to see strong growth in the next few years. It will grow to $4.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The anticipated growth during the forecast period can be attributed to the increasing acceptance of implantable defibrillators, a higher demand for personalized cardiac care, the growing prevalence of cardiac rhythm disorders, and the rising demand in emerging markets. Key trends expected to shape the forecast period include technological innovations, the development of subcutaneous ICDs that eliminate the need for transvenous leads, a rising demand for combination ICD devices with pacemaker capabilities, improvements in sensing and detection algorithms, ongoing progress in wireless charging and battery technologies, and the integration of artificial intelligence (AI) and data analytics in healthcare.

The growing prevalence of cardiovascular diseases (CVDs) is expected to drive the expansion of the implantable cardioverter defibrillators (ICDs) market in the coming years. CVDs are a range of disorders that impact the heart and blood vessels, including conditions such as heart attacks, strokes, and hypertension. These diseases are often linked to factors such as poor diet, sedentary lifestyle, smoking, and genetic predisposition. The rise in cardiovascular diseases is mainly attributed to aging populations, unhealthy lifestyle habits, and increasing rates of risk factors such as obesity, diabetes, and hypertension. ICDs play a critical role in managing CVDs by delivering life-saving electrical shocks to restore normal heart rhythms in individuals at risk of sudden cardiac arrest. For example, in December 2023, the Australian Institute of Health and Welfare reported a rise in doctor-certified deaths due to coronary heart disease (CHD), which increased from 14,100 in 2021 to 14,900 in 2022. Therefore, the increasing prevalence of cardiovascular diseases is fueling the growth of the ICD market.

Leading companies in the implantable cardioverter defibrillators (ICDs) market are concentrating on technological innovations, such as low current consumption defibrillators, to improve device performance, extend battery life, and enhance patient comfort. These defibrillators are designed to administer electrical shocks to the heart while using less energy, thereby increasing battery longevity and ensuring effective treatment of arrhythmias. For example, in October 2023, MicroPort CRM, a medical device company based in France, introduced the ULYS implantable cardioverter defibrillator (ICD) and the INVICTA defibrillation lead in Japan, marking a significant milestone in cardiac care technology. These devices incorporate advanced features such as low current consumption to extend battery life and MRI compatibility for patients requiring imaging procedures. The ULYS ICD also includes the PARAD+ arrhythmia discrimination algorithm and AutoMRI functionality, improving patient safety during MRI scans. Moreover, the INVICTA lead demonstrated a 100% implantation success rate and a 97.4% complication-free rate in clinical trials, showcasing its high reliability and effectiveness.

In June 2023, Royal Philips, a health technology company based in the Netherlands, joined forces with Biotronik to broaden the range of cardiovascular devices available to users of Philips SymphonySuite, a leading solution designed for cardiovascular office-based labs (OBLs) and ambulatory surgery centers (ASCs). The collaboration integrates Philips SymphonySuite with Biotronik’s comprehensive selection of cardiac rhythm management and cardiovascular intervention products, thereby improving options for personalized patient care and supporting the shift towards out-of-hospital care settings. Biotronik, a US-based medical device company, specializes in providing products and services that aim to enhance the quality of life for patients with cardiovascular and endovascular conditions.

Major players in the implantable cardioverter defibrillators (ICDs) market are Abbott Laboratories, Medtronic Inc., Koninklijke Philips N.V., Boston Scientific Corporation, ZOLL Medical Corporation, St. Jude Medical Inc., BIOTRONIK SE & Co. KG, Nihon Kohden Corporation, Fukuda Denshi Co. Ltd., LivaNova PLC, MicroPort Scientific Corporation, Japan Lifeline Co. Ltd., AtriCure Inc., Physio-Control Inc., BPL Medical Technologies Private Limited, Kestra Medical Technologies Inc., CU Medical Germany GmbH, Metrax GmbH, Intermedics Inc., and Sorin Group S.p.A.

North America was the largest region in the implantable cardioverter defibrillators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in implantable cardioverter defibrillators (ICDs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the implantable cardioverter defibrillators (ICDs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Implantable cardioverter defibrillators (ICDs) are compact devices placed beneath the skin, usually near the chest area. They are designed to monitor the heart's rhythm and administer electrical shocks when a life-threatening arrhythmia, such as ventricular fibrillation, is identified. The primary goal of ICDs is to prevent sudden cardiac arrest by restoring a normal heart rhythm.

There are several types of implantable cardioverter defibrillators (ICDs), including single-chamber ICDs, dual-chamber ICDs, and biventricular devices. A single-chamber ICD is implanted in the chest and is responsible for detecting and correcting abnormal heart rhythms in one of the heart's chambers. This device serves various purposes, such as managing bradycardia, tachycardia, and heart failure, and is utilized in different settings, including hospitals, specialty clinics, ambulatory surgical centers, and more.

The implantable cardioverter defibrillators (ICDs) market research report is one of a series of new reports that provides implantable cardioverter defibrillators (ICDs) market statistics, including the implantable cardioverter defibrillators (ICDs) industry global market size, regional shares, competitors with the implantable cardioverter defibrillators (ICDs) market share, detailed implantable cardioverter defibrillators (ICDs) market segments, market trends, and opportunities, and any further data you may need to thrive in the implantable cardioverter defibrillators (ICDs) industry. This implantable cardioverter defibrillators (ICDs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The implantable cardioverter defibrillators (ICDs) market consists of sales of therapy defibrillators, rechargeable and non-rechargeable batteries, programming devices, implantation tools, electrodes, and leads. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.